Answers are grounded in this paper and cite their sources.
Case report demonstrates sustained complete remission in refractory T lymphoblastic lymphoma, highlighting the preventive potential of donor-derived CD7 CAR-T cells after transplantation.
Chimeric antigen receptor T cells (CAR T) targeting CD7 for T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/LBL) showed promising efficacy and safety in some clinical trials. However, most of them were bridged with allogeneic hematopoietic stem cell transplantation (allo-HSCT). We described successful treatment with preventive donor-derived anti-CD7 CAR-T therapy in a case of refractory T lymphoblastic lymphoma following allo-HSCT, who could not receive autologous anti-CD7 CAR-T products due to the low-quality of T lymphocytes. To date, the patient’s complete remission has persisted for 20 months after HSCT.
No takes yet. Share an insight, caveat, or question.
Jiang et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: